Search

Your search keyword '"cancer combination chemotherapy"' showing total 2 results
Start Over Descriptor "cancer combination chemotherapy" Journal european journal of cancer (oxford, england : 1990)
2 results on '"cancer combination chemotherapy"'

1. Cancer and pregnancy: what should we know about the management with systemic treatment of pregnant women with cancer?

Author

Pavlidis, Nicholas and Pavlidis, Nicholas [0000-0002-2195-9961]

Subjects
Oncology, Health Knowledge, Attitudes, Practice, Ectopic pregnancy, Acute lymphoblastic leukemia, Anthracycline, Medical Oncology, Breast cancer, Pregnancy, Epidemiology of cancer, Antineoplastic agents, Drug safety, Melanoma, Hypospadias, Practice, Hydramnios, Systemic therapy, Obstetrics, Chronic myeloid leukemia, Cancer hormone therapy, Sarcoma, Vagina bleeding, Medical Oncology/*methods, Oxaliplatin, Erlotinib, Promyelocytic leukemia, Vincristine, Dactinomycin, Nonhodgkin lymphoma, Lung cancer, Prematurity, Rituximab, Human, medicine.medical_specialty, Bicuspid aortic valve, Kidney failure, Antineoplastic Agents, Major clinical study, Side effect, Article, Bleomycin, Humans, Pregnancy Complications, Neoplastic/epidemiology/*therapy, Cyclophosphamide, Spontaneous abortion, Pregnant women, Lapatinib, Premature fetus membrane rupture, medicine.disease, Monotherapy, Intrauterine growth retardation, Colorectal cancer, Cancer combination chemotherapy, Acute granulocytic leukemia, Brain tumor, Tamoxifen, Methotrexate, Procarbazine, Attitudes, Imatinib, Pregnant Women, Cisplatin, Antineoplastic Agents/administration & dosage/therapeutic use, Idarubicin, Cancer Research, Down syndrome, Respiratory failure, Brain ventricle dilatation, Meningocele, Neoplasms, Hydroxyurea, Pylorus stenosis, Head and neck cancer, Priority journal, Cervical cancer, Fetus death, Vesicoureteral reflux, Cytarabine, Folinic acid, Dacarbazine, Clubfoot, Cancer radiotherapy, Hypertension, Female, Fluorouracil, Uterine cervix cancer, Pregnancy Complications, Neoplastic, medicine.drug, Hodgkin disease, Medical oncology, Ovary cancer, Developmental disorder, Navelbine, Oligohydramnios, Unplanned pregnancy, Pregnancy complication, Internal medicine, medicine, Health knowledge, Busulfan, Platinum, Neoplasms/epidemiology/*therapy, Neoplastic, business.industry, Daunorubicin, Cancer, Chlormethine, Pregnant woman, Taxane derivative, Respiratory distress, Trastuzumab, Preeclampsia, Pregnancy complications, Doxorubicin, Prednisone, Neoplasm, Syndactyly, business, Unindexed drug
Abstract

The incidence of cancer during pregnancy is a rare phenomenon and is estimated to occur in 1:1000 pregnancies. This co-existence is likely to rise since the delay of childbearing to the later reproductive age is nowadays more common in families. The most frequent malignancies diagnosed during pregnancy are breast cancer, cervical cancer, haematological malignancies (lymphomas and acute leukaemias) and melanoma. Less common tumours are gastrointestinal, urological and lung cancers [1]. © 2011 Elsevier Ltd. 47 SUPPL. 3 S348 S352

Published
2011

2. Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group

Author

Fountzilas, George, Athanasiades, A., Kalogera-Fountzila, Anna, Aravantinos, Gerasimos, Bafaloukos, Dimitrios, Briassoulis, E. Ch, Dombros, N., Loannidis, I., Pavlidis, Nicholas, Kosmidis, Paraskevas A., Skarlos, Dimosthenis V., Pavlidis, Nicholas [0000-0002-2195-9961], Aravantinos, Gerasimos [0000-0002-2106-1713], and Kalogera-Fountzila, Anna [0000-0002-6801-3129]

Subjects
Dimetindene, Cancer Research, medicine.medical_treatment, Phases of clinical research, Gastroenterology, Dexamethasone, Carboplatin, chemistry.chemical_compound, Breast cancer, Phytogenic, Antineoplastic Agents, Phytogenic/administration & dosage, Antineoplastic agents, Antineoplastic Combined Chemotherapy Protocols, Infusions, Intravenous, Anthracycline derivative, Priority journal, Cancer resistance, Area under the curve, Anemia, Nausea, Middle Aged, Ondansetron, Clinical trial, Treatment Outcome, Oncology, Paclitaxel, Female, Infection, Intravenous, Cimetidine, Human, Diarrhea, Adult, Infusions, medicine.medical_specialty, Anthracycline, Adolescent, Vomiting, Clinical article, Breast Neoplasms, Article, Breast Neoplasms/drug therapy, Advanced cancer, Antineoplastic combined chemotherapy protocols, Paclitaxel/administration & dosage, Internal medicine, medicine, Chemotherapy, Humans, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Phase 2 clinical trial, Aged, business.industry, Recombinant granulocyte colony stimulating factor, Carboplatin/administration & dosage, Cancer, Leukopenia, medicine.disease, Thrombocytopenia, Antineoplastic Agents, Phytogenic, Cancer combination chemotherapy, Neuropathy, Surgery, Drug efficacy, chemistry, Drug Resistance, Neoplasm, Drug resistance, Subcutaneous drug administration, Neoplasm, Intravenous drug administration, Breast neoplasms, Mitoxantrone, Intramuscular drug administration, business, Controlled study
Abstract

37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg · min/ml every 4 weeks with G-CSF support. There were 5 (14%, 95% CI 3-25%) complete and 11 (30%, 95% CI 15-45%) partial responders. Median duration of response was 11.5 months (range 5.2-16.8+), median time to progression 8 months (range 0.26-16.8+) and median survival 12 months (range 0.5-19.6+). Grade 3-4 leucopenia (27%), thrombocytopenia (10%) and diarrhoea (5%) were noted. In conclusion, the combination of paclitaxel and carboplatin is active and well tolerated in patients with advanced breast cancer resistant to anthracyclines. 33 11 1893 1895

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results